Evidence map›Paper›PMID 42830353›Full record

ArticleNature communications2026

High-resolution structures of human NHE6 and NHE9 elucidate endosomal ion and lipid interactions.

Jesper S Hansen, Ashley C W Pike, Gamma Chi, Gernot Wolf, Jeppe Tranberg-Jensen, Hannah Lichtmannegger, David Speedman, Alvaro Ingles-Prieto, Fabian Goericke, Helena Batoulis and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jesper S Hansen *Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0003-1638-1285
Ashley C W Pike *Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-9661-2607
Gamma ChiCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-9910-0965
Gernot WolfCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Jeppe Tranberg-JensenCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Hannah LichtmanneggerCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0009-0008-5181-8052
David SpeedmanCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Alvaro Ingles-PrietoCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Fabian GoerickeBayer AG, Pharmaceuticals, Research & Development, Wuppertal, Germany.
Helena BatoulisBayer AG, Pharmaceuticals, Research & Development, Wuppertal, Germany.
Hartmut BeckBayer AG, Pharmaceuticals, Research & Development, Wuppertal, Germany.
Rajini RaoThe Department of Physiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-1833-5971
Tooraj MirshahiDepartment of Genomic Health, Geisinger, Danville, PA, USA.ORCID 0000-0002-0754-3820
David B SauerCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-9291-4640
Giulio Superti-FurgaCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0002-0570-1768
Kilian V M HuberCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK. kilian.huber@cmd.ox.ac.uk.ORCID 0000-0002-1103-5300

Funding

Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) NIGMS 147197Innovative Medicines Initiative (IMI) 777372Innovative Medicines Initiative (IMI) 875510Wellcome TrustWellcome Trust (Wellcome) 218514/Z/19/Z
6 · The paper itself

Abstract

Endosomal NHE6 (SLC9A6) and NHE9 (SLC9A9) transporters are essential for maintaining pH homeostasis within endosomes and their dysfunction has been linked to neurological and neurodegenerative disorders. NHE6 and NHE9 are widely considered to function as electroneutral exchangers that couple the export of protons to the import of sodium or potassium ions across cellular membranes, thereby forming the basis of proton leak pathways for internal pH balancing and fine-tuning. Among the 13 identified SLC9 family members, only NHE6 and NHE9 are targeted to endosomes. Despite their biological importance and therapeutic potential, the structural basis for their activity and regulation remains elusive. Here, we present the cryo-EM structures of human NHE9 and two splice variants of NHE6 that differ by alternative inclusion of the β-hairpin motif-containing loop domain located between transmembrane helices 2 and 3, showcasing structural diversity within the organellar NHE subfamily. By mapping the sodium-binding site, our results provide mechanistic insights into ion transport, and for NHE6 we provide evidence for a conserved PIP2-mediated regulatory mechanism. These findings provide a framework for understanding endosomal NHE function with implications for disorders such as Alzheimer's disease and glioblastoma.

Indexed as

EndosomesSodium-Hydrogen ExchangersBinding SitesCryoelectron MicroscopyHumansIon TransportModels, MolecularSodiumSLC9A6 protein, humanSLC9A9 protein, humanSodiumSodium-Hydrogen Exchangers

Identifiers

PMID42830353
PMCPMC13635234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.